Blog - Page 2 of 5589 - QualityStocks

TuesdayMar 24, 2026 11:02 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Launches MyOnlineConsultation Platform Through MOCTeledoc

Earth Science Tech (OTC: ETST) announced the official launch of MyOnlineConsultation.com through MOCTeledoc LLC, a fully integrated doctor network providing technology and clinical staffing solutions to digital health companies, following a beta phase that achieved cash-flow-positive status. The platform supports ETST’s vertically integrated healthcare ecosystem by connecting its prescriber network with compounding pharmacies, including RxCompound and Mister Meds, while offering turnkey telehealth technology, clinical staffing and integrated fulfillment as the company positions MOCTeledoc as a new revenue stream alongside divisions that generated $25.9 million for the nine months ended Dec. 31, 2025. To view the full press release, visit https://ibn.fm/0X6W1 About Earth Science Tech, Inc. (ETST) Earth Science…

TuesdayMar 24, 2026 10:55 am

QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including advancing two drug candidates toward FDA approval and opening its first HOPE Therapeutics clinics focused on neuroplastic care. The company reported a reduced operating loss of $16.2 million, down from $18.5 million in 2024, alongside lower research and development and general and administrative expenses, and ended the year with approximately $7.8 million in cash, which management believes will support operations through the end of 2026. To view the full press release, visit https://ibn.fm/Qgb32…

TuesdayMar 24, 2026 10:30 am

CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Sees Important Geological Indicators for Advancing Clayton Silver Project Exploration

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising. CMX Gold & Silver Corp., an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, sees compelling prospects for unexplored areas of the project, magnified by the growing value of silver According to J.P. Morgan Global Research, silver prices are projected to average $81/oz in 2026, double their average in 2025, encouraging aggressive exploration of the historically productive but largely unexplored site In January 2026, the company commenced a non-brokered private placement financing for aggregate gross proceeds of up to CAN$2,000,000…

TuesdayMar 24, 2026 10:17 am

QualityStocksNewsBreaks – American Fusion Inc. (OTC: AMFN) Highlights Participation In Global Energy And Hydrogen Research Events

American Fusion (OTC: AMFN) is participating in key industry events, including the 17th International Workshop on Anomalies in Hydrogen Loaded Metals (IWAHLM-17), held March 24-26, 2026 in Bergamo, Italy, and the Applied Power Electronics Conference (APEC), taking place March 22-26, 2026 in San Antonio, Texas. The engagements bring together researchers, engineers and industry participants focused on hydrogen-metal systems, power electronics and advanced energy technologies, and are part of the company’s ongoing efforts to remain involved in technical discussions, monitor developments across related fields and build relationships within the broader energy and infrastructure ecosystem. To view the full press release, visit https://ibn.fm/67rUb About American Fusion Inc. American Fusion Inc. (OTC: AMFN) is an…

TuesdayMar 24, 2026 9:45 am

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation Proton therapy's ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary…

TuesdayMar 24, 2026 9:40 am

QualityStocksNewsBreaks – Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Signs MOU With Vulcan Elements To Develop Rare Earth Magnet Supply Chain

Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) announced it has executed a memorandum of understanding dated March 16, 2026 with Vulcan Elements Inc. to collaborate on developing a domestic rare earth magnet supply chain for defense and commercial applications, with plans for Ucore to supply NdPr oxide and Dy oxides at commercial scale beginning in 2027. The collaboration links Ucore’s separation platform in Ontario and planned Louisiana Strategic Metals Complex with Vulcan’s North Carolina manufacturing operations, as both companies work toward advancing production, technical specifications and a longer-term commercial supply agreement. To view the full press release, visit https://ibn.fm/a2C7a About…

TuesdayMar 24, 2026 9:30 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) To Present Deciparticle Platform And Pipeline At BIO-Europe Spring 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle (TM) nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026 on March 25, where it has been selected as a presenting company. The company will highlight its next-generation drug delivery technology along with two lead candidates, Sapu003 (Everolimus for Injection), currently in Phase 1 trials, and Sapu006 (Docetaxel for Injection), entering Phase 1, as it seeks strategic partnerships to advance development and commercialization. To view the full press release, visit https://ibn.fm/Slq47 About Sapu Nano Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug…

TuesdayMar 24, 2026 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach

Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL. Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning…

MondayMar 23, 2026 2:57 pm

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer

Soligenix (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused on patient safety and capital efficiency, as highlighted in a recent citybiz feature. The company’s lead candidate, HyBryte(TM), targets cutaneous T-cell lymphoma using visible light activation rather than traditional chemotherapy or UV-based therapies, with clinical data indicating faster response times and a favorable safety profile, while also supporting potential at-home treatment through telehealth-enabled delivery. The company is nearing completion of a confirmatory Phase 3 study for HyBryte(TM), with interim analysis expected in early 2026 and top-line results later in the year, alongside supportive data showing strong patient response rates. Soligenix’s broader strategy leverages regulatory incentives for…

MondayMar 23, 2026 1:21 pm

QualityStocksNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Prices $4 Million Registered Direct Offering

ParaZero Technologies (NASDAQ: PRZO) announced it has entered into a definitive agreement for a registered direct offering with a single institutional investor expected to generate approximately $4 million in gross proceeds through the sale of 5,333,333 ordinary shares (or pre-funded warrants) at $0.75 per share. The company said proceeds will be used for general corporate purposes and working capital, with the transaction expected to close on or about March 24, 2026, and Aegis Capital Corp. acting as exclusive placement agent. To view the full press release, visit https://ibn.fm/8Z2ue About ParaZero Technologies ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for…

Site Search

Company Search